Market Herald logo

Find out more about this capital raise

Be the first with the news that moves the market
  • GlucoTrack (GCTK) announced the pricing of an underwritten public offering of shares to the value of around $10 million dollars
  • The offer consists of 7,352,942 shares of common stock and pre-funded warrants at a price to the public of $1.36
  • New York-based Aegis Capital is the sole underwriter for the offering
  • Glucotrack is focused on easing glucose monitoring with a range of products focused on managing the needs of both Type 1 and Type 2 diabetes
  • GlucoTrack (GTCK) is down 50 per cent on the day with shares trading at US$1.37

GlucoTrack (GCTK) announced the pricing of an underwritten public offering of shares to the value of roughly $10 million dollars.

The offer consists of 7,352,942 shares of common stock and pre-funded warrants at a price of $1.36.

New York-based Aegis Capital is the sole underwriter for the offering. The offering is expected to close on April 17, 2023.

About GlucoTrack

GlucoTrack, is a medical device, and digital health platform company.

By narrowing in on diabetes and prediabetes the company hopes to use the net proceeds from this offering for working capital and general corporate purposes.

Glucotrack eases glucose monitoring with a range of products managing the needs of both Type 1 and Type 2 diabetes.

Additionally, the company has developed GlucoTrack®, a proprietary non-invasive glucose monitoring device designed to obtain glucose level measurements.

The result is no pain or discomfort of conventional invasive finger stick devices and a reduction in cost.

GlucoTrack (GTCK) is down 50 per cent on the day, trading at US$1.37 at close.

The material provided in this article is for information only and should not be treated as investment advice. For full disclaimer information, please click here

More From The Market Herald

Yooma Wellness sells Vitality CBD to Canadian biotech firm

Yooma Wellness’ (CSE:YOOM) wholly-owned subsidiary, Yooma Europe Limited has completed the sale of Birmingham-based Vitality CBD Ltd.
The Market Herald Video

NurExone moves towards human clinical trials, completes pre-IND meeting with FDA

NurExone Biologic Inc. (TSXV:NRX) has completed a pre-investigational new drug meeting with the U.S. FDA regarding its exotherapy product.

An AI platform that can manage weight loss and addiction

Vice Health and Wellness (CSE:VICE) is developing an AI platform to provide a personalized weight loss and management experience.